The Apex Times
Above the Noise
Business Wire
BusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessMeta and Alphabet’s exposure to Jio Platforms faces a valuation test as India’s IPO hype buildsThe Apex TimesBusinessCathie Wood’s Ark cuts AMD in a $124 million shift within its AI stock basket, Yahoo Finance reportsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex Times
Back to front
Ray Dalio highlights Eli Lilly as growth stock after FDA approves new dosing regimen
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 18, 5:35 PM EDT

Ray Dalio highlights Eli Lilly as growth stock after FDA approves new dosing regimen

Bridgewater Associates’ Ray Dalio pointed to Eli Lilly’s progress after the U.S. Food and Drug Administration approved a new dosing regimen, according to a report carried by Yahoo Finance.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Billionaire investor Ray Dalio, through Bridgewater Associates, cited Eli Lilly and Company as one of the growth stocks to buy, according to a Yahoo Finance report dated June 18.

The article ties its recommendation to a regulatory milestone for Eli Lilly. It says that on June 10, the U.S. Food and Drug Administration approved a new dosing regimen for the company, an update that could affect how patients and clinicians use the therapy going forward.

Beyond the FDA approval, the Yahoo Finance piece frames Eli Lilly’s opportunity in the broader context of growth investing, pointing readers to Dalio’s perspective rather than presenting new clinical or financial results from the company itself.

Eli Lilly’s stock trades on the New York Stock Exchange under the ticker LLY. Any shift in dosing guidance from regulators can have practical consequences across the prescription lifecycle, including how quickly patients can be brought to effective doses and how physicians schedule follow-up visits.

Still, the report as presented does not spell out key specifics such as which product received the dosing-regimen approval, what the regimen changes relative to prior labeling, or whether the agency’s action was tied to new trial data versus label optimization. Those details matter for understanding the size and timing of any potential commercial impact.

It also does not disclose any Bridgewater position size, time horizon, or valuation view in the text provided. As a result, the recommendation should be understood as an investor commentary anchored to the regulatory headline rather than a complete investment thesis.

For Eli Lilly, regulatory labeling updates are often closely watched because they can influence prescribing behavior, payer approvals, and the way treatment pathways are managed in real-world settings. In the healthcare sector, even incremental label changes can translate into meaningful differences in demand, though the direction and magnitude are rarely knowable immediately after an approval.

What to watch next is whether Eli Lilly provides further clarification on the new dosing regimen in official materials, including any expanded guidance for clinicians, payer or formulary discussions, and whether management updates its outlook or commercialization plans to reflect the change.

Why It Matters

  • FDA dosing-regimen changes can alter real-world treatment patterns, affecting prescribing behavior and potential demand.
  • Investors often treat FDA labeling updates as catalysts, particularly when they can improve patient access, adherence, or clinician adoption.
  • The lack of regimen specifics means markets may need additional company or regulatory detail before quantifying impact.
  • Dalio’s endorsement indicates attention from large investors, which can influence near-term investor sentiment even without new numbers in the report.

Sources

Key Facts

  • A Yahoo Finance report says Ray Dalio and Bridgewater Associates highlighted Eli Lilly as a growth stock to buy.
  • The report links the recommendation to an FDA approval dated June 10 for a new dosing regimen tied to an Eli Lilly therapy.
  • The Yahoo Finance item provided does not state which drug or the specific changes in the dosing regimen.
  • The report frames the recommendation as investor commentary rather than a company financial update.
  • Eli Lilly’s common stock trades on the NYSE under the ticker LLY.

Healthcare Related

Ray Dalio highlights Eli Lilly as growth stock after FDA approves new dosing regimen | The Apex Times